Education
About Us
Working with TipRanks
Follow Us
Regeneron Pharmaceuticals (REGN)
:REGN
Top Page
Regeneron
(NASDAQ:REGN)
Select Model
Select Model
Rating:74Outperform
Price Target:
$632.00
▲(8.36% Upside)
Regeneron's strong financial performance and attractive valuation are key strengths, supported by robust profitability and a solid balance sheet. The earnings call provided positive guidance on product performance and future growth potential. However, technical analysis indicates some bearish momentum, and challenges in revenue growth and competitive pressures remain concerns.
Positive Factors
Strong Product Growth
Dupixent's strong sales growth indicates robust demand and market penetration, supporting Regeneron's revenue stability and expansion potential.
R&D Investments
Significant R&D investments highlight Regeneron's commitment to innovation, ensuring a strong pipeline and long-term competitive advantage.
Regulatory Approval Progress
Advancements in regulatory approvals for Dupixent expand its market reach, enhancing revenue potential and reinforcing product portfolio strength.
Negative Factors
EYLEA Sales Decline
The decline in EYLEA sales due to competitive pressures and pricing issues poses a risk to Regeneron's revenue diversification and market position.
FDA Inspection Delays
Regulatory delays can hinder product launch timelines, affecting revenue forecasts and strategic planning.
Competitive Market Dynamics
Increased competition in key therapeutic areas could pressure Regeneron's market share and necessitate strategic adjustments.
Regeneron (REGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$61.82B
Dividend Yield0.47%
Average Volume (3M)1.07M
Price to Earnings (P/E)14.7
Beta (1Y)0.79
Revenue Growth5.38%
EPS Growth3.58%
CountryUS
Employees15,158
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)12.89
Shares Outstanding104,170,296
10 Day Avg. Volume1,165,945
30 Day Avg. Volume1,069,360
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue3.67
Enterprise Value/Gross Profit4.48
Enterprise Value/Ebitda9.63
Forecast
1Y Price Target
$735.65Price Target Upside26.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
Regeneron Business Overview & Revenue Model
Company DescriptionRegeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
How the Company Makes MoneyRegeneron generates revenue primarily through the sale of its proprietary drugs. The company's key revenue streams include product sales from its leading therapies, notably Eylea and Dupixent. Eylea has established itself as a significant revenue driver in the ophthalmology market, while Dupixent has gained traction in the immunology space. Additionally, Regeneron engages in collaborative partnerships and licensing agreements with other pharmaceutical companies, which can provide milestone payments and royalties based on sales. The company's robust pipeline of drug candidates in various stages of development also holds the potential for future revenue growth, particularly as new products gain regulatory approval and enter the market.
Regeneron Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how revenue is distributed across different business units, highlighting which areas are driving growth and which might need strategic adjustments.
Shows how revenue is distributed across different business units, highlighting which areas are driving growth and which might need strategic adjustments.
Data provided by:
Main Street Data
Main Street DataRegeneron Earnings Call Summary
Earnings Call Date:Aug 07, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Oct 28, 2025
Earnings Call Sentiment Positive
Regeneron showed strong performance in key products like Dupixent and Libtayo, successful launches, and robust financial results, offsetting the declines in EYLEA sales and regulatory delays. The company's significant R&D investments indicate a focus on future growth, despite facing competitive pressures and market dynamics.Q2-2025 Updates
Positive Updates
Strong Growth in Key Products
Dupixent global net product sales increased by 21% to $4.3 billion, and Libtayo sales grew by 25% to $377 million on a constant currency basis compared to the previous year.
Successful Launches and Pipeline Advances
Lynozyfic was FDA approved for relapsed/refractory multiple myeloma, and several new indications for Dupixent were approved, potentially treating over 600,000 additional patients.
Robust Financial Performance
Second quarter diluted net income per share grew 12% to $12.89, and the company generated $1.7 billion in free cash flow for the first half of 2025.
Significant R&D Investments
Investments over $7 billion in the U.S. for expanding R&D and manufacturing capabilities, with a strong pipeline of approximately 45 product candidates.
Negative Updates
EYLEA U.S. Sales Decline
EYLEA U.S. net product sales were $754 million, down 39% compared to the second quarter of last year, with ongoing competitive pressures and pricing issues expected to continue.
FDA Inspection Delays
EYLEA HD enhancements and the BLA for odronextamab were delayed due to an FDA site inspection at Catalent Indiana LLC, affecting regulatory timelines.
Competition and Market Dynamics
The anti-VEGF category experienced a decline in branded volume due to competition from Avastin, influenced by affordability issues.
Company Guidance
During Regeneron's Q2 2025 earnings call, the company provided several key financial metrics and guidance updates. Dupixent's global net product sales increased by 21% to $4.3 billion, and Libtayo's sales grew by 25% on a constant currency basis. EYLEA HD in the U.S. saw a significant 29% growth compared to the same quarter last year, with net product sales reaching $393 million. However, EYLEA's U.S. net product sales were $754 million, marking a 39% decline year-over-year. The company anticipates continued challenges for EYLEA due to competitive pressures and pricing issues. Regeneron updated its 2025 financial guidance, noting a combined net decrease of $125 million at the midpoints for SG&A, R&D, and cost of goods sold expenses. The company expects its effective tax rate to trend towards the mid-teens over time. Additional pipeline updates and strategic capital allocation plans were discussed, emphasizing ongoing investments in research and development and manufacturing capabilities, with over $7 billion earmarked for expansion in the U.S.Regeneron Financial Statement Overview
Summary
Regeneron exhibits strong profitability and financial stability with a high gross profit margin and low debt-to-equity ratio. However, challenges in revenue growth and declining free cash flow growth present potential risks.Income Statement
Regeneron's income statement reflects strong profitability with a Gross Profit Margin of 87.44% and a Net Profit Margin of 31.37% for TTM. While the revenue growth rate has slowed recently, historical revenue growth has been impressive. EBIT and EBITDA margins remain healthy, indicating efficient operations. However, the decline in revenue from 2021 to 2022 highlights potential market challenges.75
Positive
Balance Sheet
Regeneron maintains a robust balance sheet characterized by a low Debt-to-Equity Ratio of 0.09 and a strong Equity Ratio of 78.32% for TTM, indicating low leverage and high financial stability. The Return on Equity is solid at 14.89%, reflecting efficient use of equity capital. The company has a strong asset base, enhancing its financial resilience.80
Positive
Cash Flow
The cash flow statement indicates healthy cash generation, with an Operating Cash Flow to Net Income Ratio of 1.06 for TTM. The Free Cash Flow to Net Income Ratio is also strong at 0.86, suggesting effective cash management. However, there is a declining trend in free cash flow growth, which may impact future liquidity.70
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 14.21B | 14.20B | 13.12B | 12.17B | 16.07B | 8.50B |
| Gross Profit | 11.65B | 11.75B | 10.87B | 10.47B | 13.35B | 7.14B |
| EBITDA | 5.42B | 5.32B | 4.69B | 5.26B | 9.67B | 4.10B |
| Net Income | 4.46B | 4.41B | 3.95B | 4.34B | 8.08B | 3.51B |
Balance Sheet | ||||||
| Total Assets | 38.22B | 37.76B | 33.08B | 29.21B | 25.43B | 17.16B |
| Cash, Cash Equivalents and Short-Term Investments | 7.47B | 9.01B | 10.84B | 7.74B | 5.69B | 3.59B |
| Total Debt | 2.71B | 2.70B | 2.70B | 2.70B | 2.70B | 2.70B |
| Total Liabilities | 8.28B | 8.41B | 7.11B | 6.55B | 6.67B | 6.14B |
| Stockholders Equity | 29.94B | 29.35B | 25.97B | 22.66B | 18.77B | 11.03B |
Cash Flow | ||||||
| Free Cash Flow | 3.84B | 3.66B | 3.67B | 4.42B | 6.53B | 2.00B |
| Operating Cash Flow | 4.74B | 4.42B | 4.59B | 5.01B | 7.08B | 2.62B |
| Investing Cash Flow | -670.30M | -2.47B | -3.19B | -3.78B | -5.38B | -70.60M |
| Financing Cash Flow | -3.99B | -2.20B | -1.79B | -1.01B | -1.01B | -1.97B |
Regeneron Technical Analysis
Negative
583.24
Price Trends
572.60
Negative
557.79
Positive
604.96
Negative
Market Momentum
2.70
Positive
45.06
Neutral
40.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For REGN, the sentiment is Negative. The current price of 583.24 is above the 20-day moving average (MA) of 578.38, above the 50-day MA of 572.60, and below the 200-day MA of 604.96, indicating a bearish trend. The MACD of 2.70 indicates Positive momentum. The RSI at 45.06 is Neutral, neither overbought nor oversold. The STOCH value of 40.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for REGN.
Regeneron Risk Analysis
Regeneron disclosed 47 risk factors in its most recent earnings report. Regeneron reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Regeneron Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $17.02B | 19.41 | 24.30% | ― | 18.87% | 1088.27% | |
75 Outperform | $105.19B | 30.10 | 22.77% | ― | 10.38% | ― | |
74 Outperform | $61.82B | 14.70 | 15.34% | 0.47% | 5.38% | 3.58% | |
74 Outperform | $48.66B | 37.53 | 24.75% | ― | 89.58% | ― | |
60 Neutral | $59.25B | ― | -257.82% | ― | 5.01% | -330.09% | |
56 Neutral | $25.28B | ― | -1.81% | ― | 7.51% | 30.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
REGN
Regeneron
563.86
-430.90
-43.32%
ALNY
Alnylam Pharma
450.68
172.06
61.75%
INCY
Incyte
85.38
20.01
30.61%
VRTX
Vertex Pharmaceuticals
421.15
-55.00
-11.55%
ARGX
Argenx Se
798.94
271.69
51.53%
BNTX
BioNTech SE
106.28
-12.09
-10.21%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.